The Yangtze River Delta's New Quality Leading Biomedical Industry Ranking is divided into three main categories for evaluation: biomedicine, medical devices, and digital healthcare. Based on the quantitative growth evaluation standards for enterprises developed over years by Huayi Research Institute, and incorporating processes such as enterprise registration, interviews, research, enterprise review, and report writing, a professional review committee comprehensively evaluates shortlisted companies on aspects like financials, operational data, innovation capabilities, investor returns, and social responsibility to form an objective third-party industry ranking.

As a pioneer in the "AI + drug delivery" field,METiS TechBio has continuously made breakthroughs in technology research and development, overcoming challenges such as data scarcity and the lack of precedents for algorithms. It has independently developed groundbreaking artificial intelligence and computational simulation algorithms ranging from ionizable lipid generation and design to LNP (lipid nanoparticle) nanomaterial design and simulation. By integrating world-leading high-throughput experimental techniques and animal validation platforms, the company has successfully built a robust data and algorithmic barrier, achieving breakthrough progress in nanomaterial design and drug delivery.

Learn More About METiS TechBio

METiS TechBio Awarded "National High-Tech Enterprise" Recognition